Specialty medicines sales revenue (quarterly)

STO-REC-STATCYNAPQT2 National
3.8 billionGBP

Global · Q2 2026

Specialty medicines sales revenue (quarterly) totalled 3.8 billion GBP in Q2 2026 (GSK).

Original source
Publisher
GSK
Authority tier
T2 National
Locator
Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth
Retrieved
17 Sep 2026
Status
Verified

What the source says

Specialty Medicines sales £3.8 billion (+14%); Respiratory, Immunology & Inflammation £1.1 billion (+19%); Oncology £0.6 billion (+17%); HIV sales £2.1 billion (+10%)

Verbatim extraction verified: The figure 3.8 billion GBP is directly attested in the quoted passage (Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth).

The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.

Cite this figure

Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.

APA
GSK. (2026). GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026. Retrieved September 17, 2026, from https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Via StatOrigin, https://statorigin.org/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS
MLA
GSK. "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026." 2026, https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed 17 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS.
Chicago
GSK. "GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026." 2026. https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS.
BibTeX
@misc{gsk2026specialtykmxmcs, author = {{GSK}}, title = {GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R\&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS}, note = {Original source: https://www.gsk.com/en-gb/media/press-releases/gsk-delivers-strong-q2-core-results-performance-and-continued-momentum/. Accessed September 17, 2026.} }

Provenance and verification

Everything needed to check this number yourself, without taking our word for it.

Chain of Custody · Verification Audit
Record: STO-REC-STATCYNAPQ T2 National

Primary Source

Publisher
GSK · homepage ↗
Authority tier
Tier 2 · National Official
Report
GSK delivers strong Q2 core results performance and continued momentum. Plans announced to accelerate R&D and late-stage pipeline portfolio. Expect 20+ phase III trial starts in 2026
Type
Press release
Published
Locator
Strong Specialty Medicines and Vaccines performance drives sales and core operating profit growth
Retrieved
17 September 2026
Link status
Reachable (HTTP 200)
Report licence
See source

Verification & Integrity

Audit status
Verified
Review protocol
Editorial review
Checked on
17 September 2026
Last revision
17 September 2026
Archival URI
/stat/stat_CYNAPQ76STC6DXDDWH3BKMXMCS